Please Wait.....
Report
Esoteric Testing Market Size, Share & Trends by Type (Endocrinology, Oncology, Neurology, Genetic Tests, Autoimmune, Infectious Diseases), Technology (ELISA, CLIA, Flow Cytometry, NGS, RT-PCR, Chromatography, Spectrometry), Specimen (Blood, Urine) - Global Forecast to 2029
Market Report I 2024-06-04 I 295 Pages I MarketsandMarkets
The global esoteric testing market is valued at an estimated USD 32.2 billion in 2024 and is projected to reach USD 48.3 billion by 2029, at a CAGR of 8.5% during the forecast period. Growth in the esoteric testing market is primarily driven by the increasing prevalence of chronic and infectious diseases, advancements in esoteric tests for personalized medicine, and increasing research funding for precision medicine.
"The Oncology testing segment accounted for the highest CAGR of the esoteric testing market in 2023, by type"
Based on type, the esoteric testing market is segmented into infectious disease testing, autoimmune disease testing, endocrinology testing, oncology testing, genetic testing, toxicology and drug monitoring testing, neurology testing, and other types of testing. Esoteric oncology tests are used to determine the hereditary risk of cancer and are essential in diagnosis, prognosis, and treatment decisions. The growth of the oncology testing segment is driven by the rising prevalence of cancer and the increased adoption of various esoteric tests.
"The chemiluminescence immunoassay (CLIA) segment is projected to witness highest growth rate in the esoteric testing market, by technology, during the forecast period."
The esoteric testing market is segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), real-time PCR, chromatography and mass spectrometry, flow cytometry, DNA sequencing and next-generation sequencing, and other technologies, based on technology . Growth in the number of specialized diagnostic laboratories equipped with advanced CLIA technology and the need for early diagnosis have necessitated the use of CLIA tests across the globe. Aggressive R&D expenditures by players and the development of innovative technologies such as chemiluminescent biochips, multiplexed assays, and portable immunoassays are also expected to support the growth of the CLIAs market in the coming years.
"The blood, serum, and plasma segment accounted for the largest market share of esoteric testing market, in 2023, by specimen"
Based on specimens, the esoteric testing market is segmented into blood, serum, and plasma, urine, and other specimens. The large share of this segment is attributed to the growing number of blood donations globally and the increasing incidence of chronic & infectious diseases worldwide.The use of blood as a specimen in esoteric testing is driven by its minimally invasive nature, comprehensive biomarker potential, and technological advancements. These factors, coupled with the growing emphasis on personalized medicine, regulatory support, and the need for efficient infectious disease testing, are propelling the growth of blood-based esoteric tests.
"The independent & reference laboratories segment accounted for the largest share of the esoteric testing market in 2023, by end user".
Based on end users, the esoteric testing market is segmented into independent & reference laboratories and hospital-based laboratories. The demand for personalized medicine, the increasing prevalence of chronic and genetic diseases, and the need for cost-effective and efficient diagnostic solutions are key growth factors driving the importance of reference laboratories operating in the esoteric testing market in the coming years.
"The Asia Pacific region is projected to witness highest growth rate in the esoteric testing market during the forecast period"
The global esoteric testing market is segmented into six regions - North America, Europe, Latin America, Asia Pacific, the Middle East & Africa, and the GCC Countries. The Asia Pacific market, which comprises Japan, Australia, India, China, and the Rest of Asia Pacific, is expected to offer significant growth opportunities to market players and is projected to register the highest CAGR in the esoteric testing market during the forecast period. Government efforts to increase awareness about early disease detection and regular health checkups, rising healthcare expenditure, and the increasing number of hospitals and clinical diagnostic laboratories, and growing awareness regarding the use of esoteric tests among physicians are some of the major factors driving the growth of the esoteric testing market in the Asia Pacific.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 45%, Tier 2 - 38%, and Tier 3 - 17%
- By Designation: C-level - 24%, D-level - 32%, and Others - 44%
- By Region: North America - 35%, Europe - 26%, Asia Pacific - 24%, Latin America - 12%, Middle East & Africa - 1%, and the GCC Countries - 2%
Lists of Companies Profiled in the Report:
Quest Diagnostics (US), Labcorp (US), H.U. Group Holdings, Inc. (Japan), Sonic Healthcare (Australia), OPKO Health, Inc. (US), Myriad Genetics, Inc. (US), The Mayo Foundation for Medical Education and Research (MFMER) (US), Eurofins Scientific (Luxembourg), Stanford Health Care (US), Foundation Medicine, Inc. (US), Kindstar Globalgene Technology, Inc. (China), Georgia Esoteric & Molecular Laboratory, LLC (US), Thyrocare Technologies Ltd. (India), ACM Global Laboratories (US), NMS Labs (US), HealthQuest Esoterics (US), Cerba Research (US), LeoLabs (India), Flow Health (US), Invitae Corporation (US), ARUP Laboratories (US), Fulgent Genetics (US), bioMONTR Labs (US), and LabGenomics (South Korea).
Research Coverage:
In this report, the esoteric testing market has been categorized based on technology (enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), real-time PCR, flow cytometry, DNA sequencing and next-generation sequencing, chromatography and mass spectrometry, and other technologies), type (oncology testing, infectious disease testing, autoimmune disease testing, genetic testing, endocrinology testing, toxicology and drug monitoring testing, neurology testing, and other types of testing), specimen (blood, serum, and plasma, urine, and other specimens) end user (independent & reference laboratories and hospital-based laboratories), and region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries).
The report's coverage includes comprehensive details about the key factors impacting the growth of the esoteric testing market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, services offered, significant strategies, acquisitions and partnerships, service launches, and recent developments related to the esoteric testing market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging esoteric testing startups.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall esoteric testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, trends, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers: (Advancements in esoteric tests for personalized medicine, increasing research funding for precision medicine, genetic analysis, and personalized medicine, growing number of collaborations), challenges (Dearth of skilled professionals and inaccuracies and misdiagnosis in diagnostic testing), opportunities (Emerging technologies and advanced tests for screening and risk identification in esoteric testing, and advances in understanding heterogeneity of diseases and safety signals), and restraints (Inadequate reimbursement, high capital investments and low-cost-benefit ratio for biomarkers) influencing the growth of the in esoteric testing market.
- Service Development/Innovation: Detailed insights on research & development activities and new service launches in the esoteric testing market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the esoteric testing market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the esoteric testing market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Quest Diagnostics (US), LabCorp (US), and H.U. Group Holdings, Inc. (Japan), among others, in the esoteric testing market strategies.
1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 37
1.2.1 INCLUSIONS & EXCLUSIONS OF STUDY 38
1.3 MARKET SEGMENTATION 38
1.3.1 MARKETS COVERED 38
FIGURE 1 ESOTERIC TESTING MARKET SEGMENTATION 38
1.3.2 REGIONS COVERED 39
1.3.3 YEARS CONSIDERED 39
1.4 CURRENCY 40
1.5 STAKEHOLDERS 40
1.6 SUMMARY OF CHANGES 40
1.6.1 RECESSION IMPACT 41
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
FIGURE 2 ESOTERIC TESTING MARKET: RESEARCH DESIGN 42
2.1.1 SECONDARY DATA 43
2.1.1.1 Key data from secondary sources 44
2.1.2 PRIMARY DATA 44
2.1.2.1 Primary sources 45
2.1.2.2 Key data from primary sources 45
2.1.2.3 Key industry insights 47
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 47
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 48
2.2 MARKET SIZE ESTIMATION 48
2.2.1 BOTTOM-UP APPROACH 48
2.2.1.1 Approach 1: Company Revenue Estimation Approach 49
FIGURE 5 COMPANY REVENUE ESTIMATION 49
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 50
2.2.2 TOP-DOWN APPROACH 51
FIGURE 7 ESOTERIC TESTING MARKET: TOP-DOWN APPROACH 51
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 52
FIGURE 8 DATA TRIANGULATION METHODOLOGY 52
2.4 MARKET SHARE ANALYSIS 53
2.5 STUDY ASSUMPTIONS 53
2.6 GROWTH RATE ASSUMPTIONS 53
2.7 RESEARCH LIMITATIONS 54
2.7.1 METHODOLOGY-RELATED LIMITATIONS 54
2.7.2 SCOPE-RELATED LIMITATIONS 54
2.8 RISK ASSESSMENT 54
TABLE 1 RISK ASSESSMENT 54
2.9 RECESSION IMPACT ON ESOTERIC TESTING MARKET 54
3 EXECUTIVE SUMMARY 55
FIGURE 9 ESOTERIC TESTING MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION) 55
FIGURE 10 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD BILLION) 56
FIGURE 11 ESOTERIC TESTING MARKET, BY SPECIMEN, 2024 VS. 2029 (USD BILLION) 56
FIGURE 12 ESOTERIC TESTING MARKET, BY END USER, 2024 VS. 2029 (USD BILLION) 57
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF ESOTERIC TESTING MARKET 58
4 PREMIUM INSIGHTS 59
4.1 ESOTERIC TESTING MARKET OVERVIEW 59
FIGURE 14 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET 59
4.2 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY AND COUNTRY (2023) 60
FIGURE 15 ELISA SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023 60
4.3 ESOTERIC TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 61
FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 61
4.4 ESOTERIC TESTING MARKET: REGIONAL MIX (2022-2029) 62
FIGURE 17 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 62
4.5 ESOTERIC TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS 62
FIGURE 18 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 63
FIGURE 19 ESOTERIC TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63
5.2.1 DRIVERS 64
5.2.1.1 Growing geriatric population and increasing prevalence of chronic and infectious diseases 64
FIGURE 20 INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2040 (MILLION) 64
FIGURE 21 INCIDENCE OF DIABETES, BY REGION, 2021 VS. 2030 VS. 2045 (MILLION) 65
TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES 65
FIGURE 22 GERIATRIC POPULATION, BY REGION, 2022 VS. 2050 (%) 66
TABLE 3 ESOTERIC TESTS INDICATED FOR CHRONIC AND INFECTIOUS DISEASES 66
5.2.1.2 Increasing use of esoteric DNA sequencing technologies in precision medicine and early diagnosis of cancer 67
5.2.1.3 Advancements in esoteric tests for personalized medicine 68
5.2.1.4 Increasing research funding for precision medicine, genetic analysis, and personalized medicine 69
5.2.1.5 Growing number of collaborations 70
5.2.1.6 Increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing 70
5.2.2 RESTRAINTS 71
5.2.2.1 Inadequate reimbursement 71
5.2.2.2 High capital investments and low-cost-benefit ratio for biomarkers 71
5.2.3 OPPORTUNITIES 72
5.2.3.1 Emerging technologies and advanced tests for screening and risk identification in esoteric testing 72
5.2.3.2 Advances in understanding heterogeneity of diseases and safety signals 73
5.2.3.3 Growth opportunities in emerging economies 73
5.2.4 CHALLENGES 74
5.2.4.1 Dearth of skilled professionals 74
5.2.4.2 Inaccuracies and misdiagnosis in diagnostic testing 75
5.3 PRICING ANALYSIS 75
TABLE 4 AVERAGE SELLING PRICE OF ESOTERIC TESTS, BY REGION 75
5.4 VALUE CHAIN ANALYSIS 76
FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 77
5.5 SUPPLY CHAIN ANALYSIS 78
FIGURE 24 ESOTERIC TESTING MARKET: SUPPLY CHAIN ANALYSIS 78
5.6 ECOSYSTEM ANALYSIS OF ESOTERIC TESTING MARKET 79
FIGURE 25 ESOTERIC TESTING MARKET: ECOSYSTEM ANALYSIS 79
5.6.1 ROLE IN ECOSYSTEM 79
TABLE 5 ESOTERIC TESTING MARKET: ROLE IN ECOSYSTEM 79
FIGURE 26 KEY PLAYERS IN ESOTERIC TESTING MARKET ECOSYSTEM 80
5.7 REGULATORY OVERVIEW 80
5.7.1 NORTH AMERICA 81
5.7.1.1 US 81
5.7.1.2 Canada 81
5.7.2 EUROPE 81
TABLE 6 ACCREDITATION BODIES IN EUROPE 81
5.7.3 ASIA PACIFIC 83
5.7.3.1 Japan 83
5.7.3.2 India 83
5.7.3.3 China 83
?
5.7.4 MIDDLE EAST 83
5.7.4.1 Saudi Arabia 83
5.7.4.2 UAE 83
5.8 TECHNOLOGY ANALYSIS 83
5.8.1 KEY TECHNOLOGIES 84
5.8.1.1 Immunoassay techniques 84
5.8.2 COMPLEMENTARY TECHNOLOGIES 84
5.8.2.1 Polymerase chain reaction 84
5.8.3 ADJACENT TECHNOLOGIES 84
5.8.3.1 Mass spectrometry 84
5.8.3.2 Flow cytometry 84
TABLE 7 KEY PLAYERS OFFERING ESOTERIC TESTS WITH ADVANCED TECHNOLOGIES 85
5.9 PATENT ANALYSIS 86
FIGURE 27 PATENT ANALYSIS FOR ESOTERIC TESTING MARKET (JANUARY 2013-DECEMBER 2023) 86
5.10 KEY CONFERENCES & EVENTS IN 2024-2025 87
TABLE 8 ESOTERIC TESTING MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, 2O24-2025 87
5.11 PORTER'S FIVE FORCES ANALYSIS 88
FIGURE 28 ESOTERIC TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS 88
TABLE 9 ESOTERIC TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS 89
5.11.1 INTENSITY OF COMPETITIVE RIVALRY 89
5.11.2 BARGAINING POWER OF SUPPLIERS 89
5.11.3 BARGAINING POWER OF BUYERS 89
5.11.4 THREAT OF SUBSTITUTES 89
5.11.5 THREAT OF NEW ENTRANTS 90
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 90
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 90
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 90
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%) 90
5.12.2 BUYING CRITERIA 91
FIGURE 30 KEY BUYING CRITERIA FOR ESOTERIC TESTING END USERS 91
TABLE 11 KEY BUYING CRITERIA FOR ESOTERIC TESTING END USERS 91
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS 91
5.13.1 REVENUE SHIFT IN ESOTERIC TESTING MARKET 92
5.14 INVESTMENT AND FUNDING SCENARIO 92
6 ESOTERIC TESTING MARKET, BY TECHNOLOGY 93
6.1 INTRODUCTION 94
TABLE 12 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 94
6.2 CHEMILUMINESCENCE IMMUNOASSAY 95
6.2.1 HIGH THROUGHPUT AND REDUCED HUMAN ERROR TO DRIVE MARKET 95
TABLE 13 ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2022-2029 (USD MILLION) 95
TABLE 14 NORTH AMERICA: ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2022-2029 (USD MILLION) 96
TABLE 15 EUROPE: ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2022-2029 (USD MILLION) 96
TABLE 16 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2022-2029 (USD MILLION) 96
TABLE 17 LATIN AMERICA: ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2022-2029 (USD MILLION) 97
6.3 ENZYME-LINKED IMMUNOSORBENT ASSAY 97
6.3.1 GROWING NUMBER OF DRUG DISCOVERY ACTIVITIES TO PROPEL MARKET 97
TABLE 18 EXAMPLES OF ESOTERIC ELISA TESTS 98
TABLE 19 ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2022-2029 (USD MILLION) 98
TABLE 20 NORTH AMERICA: ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2022-2029 (USD MILLION) 98
TABLE 21 EUROPE: ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2022-2029 (USD MILLION) 99
TABLE 22 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2022-2029 (USD MILLION) 99
TABLE 23 LATIN AMERICA: ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2022-2029 (USD MILLION) 100
6.4 REAL-TIME PCR 100
6.4.1 INCREASING USE OF QPCR FOR VARIOUS DIAGNOSTIC AND RESEARCH PURPOSES TO SUPPORT MARKET GROWTH 100
TABLE 24 ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY REGION, 2022-2029 (USD MILLION) 101
TABLE 25 NORTH AMERICA: ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY COUNTRY, 2022-2029 (USD MILLION) 101
TABLE 26 EUROPE: ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY COUNTRY, 2022-2029 (USD MILLION) 102
TABLE 27 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY COUNTRY, 2022-2029 (USD MILLION) 102
TABLE 28 LATIN AMERICA: ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY COUNTRY, 2022-2029 (USD MILLION) 103
6.5 DNA SEQUENCING AND NEXT-GENERATION SEQUENCING 103
6.5.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO AID MARKET GROWTH 103
TABLE 29 EXAMPLES OF ESOTERIC TESTS FOR DNA SEQUENCING 104
TABLE 30 ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY REGION, 2022-2029 (USD MILLION) 105
TABLE 31 NORTH AMERICA: ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION) 105
TABLE 32 EUROPE: ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION) 106
TABLE 33 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION) 106
TABLE 34 LATIN AMERICA: ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION) 107
6.6 FLOW CYTOMETRY 107
6.6.1 RISING PREVALENCE OF CANCER, HIV, AND HEMATOLOGIC MALIGNANCIES TO DRIVE MARKET 107
TABLE 35 ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2022-2029 (USD MILLION) 108
TABLE 36 NORTH AMERICA: ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2022-2029 (USD MILLION) 108
TABLE 37 EUROPE: ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2022-2029 (USD MILLION) 109
TABLE 38 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2022-2029 (USD MILLION) 109
TABLE 39 LATIN AMERICA: ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2022-2029 (USD MILLION) 110
6.7 CHROMATOGRAPHY AND MASS SPECTROMETRY 110
6.7.1 METHODOLOGICAL IMPROVEMENTS AND TECHNOLOGICAL INNOVATIONS TO BOOST MARKET GROWTH 110
TABLE 40 ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION) 111
TABLE 41 NORTH AMERICA: ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION) 111
TABLE 42 EUROPE: ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION) 112
TABLE 43 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION) 112
TABLE 44 LATIN AMERICA: ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION) 113
6.8 OTHER TECHNOLOGIES 113
TABLE 45 ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION) 114
TABLE 46 NORTH AMERICA: ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) 114
TABLE 47 EUROPE: ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) 115
TABLE 48 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) 115
TABLE 49 LATIN AMERICA: ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) 116
7 ESOTERIC TESTING MARKET, BY TYPE 117
7.1 INTRODUCTION 118
TABLE 50 ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 118
7.2 ONCOLOGY TESTING 119
7.2.1 HIGH BURDEN OF CANCER TO DRIVE MARKET 119
TABLE 51 PREVALENCE OF CANCER AMONG MALES, 2022 119
TABLE 52 PREVALENCE OF CANCER AMONG FEMALES, 2022 119
TABLE 53 EXAMPLES OF ESOTERIC TESTS FOR CANCER DIAGNOSIS 120
TABLE 54 ESOTERIC ONCOLOGY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION) 121
TABLE 55 NORTH AMERICA: ESOTERIC ONCOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 122
TABLE 56 EUROPE: ESOTERIC ONCOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 122
TABLE 57 ASIA PACIFIC: ESOTERIC ONCOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 123
TABLE 58 LATIN AMERICA: ESOTERIC ONCOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 123
7.3 AUTOIMMUNE DISEASE TESTING 123
7.3.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH 123
TABLE 59 ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY REGION, 2022-2029 (USD MILLION) 124
TABLE 60 NORTH AMERICA: ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 124
TABLE 61 EUROPE: ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 125
TABLE 62 ASIA PACIFIC: ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 125
TABLE 63 LATIN AMERICA: ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 126
7.4 INFECTIOUS DISEASE TESTING 126
7.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO AID MARKET GROWTH 126
TABLE 64 EXAMPLES OF ESOTERIC TESTS FOR INFECTIOUS DISEASES 126
TABLE 65 ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2022-2029 (USD MILLION) 128
TABLE 66 NORTH AMERICA: ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 128
TABLE 67 EUROPE: ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 68 ASIA PACIFIC: ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 69 LATIN AMERICA: ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 130
7.5 ENDOCRINOLOGY TESTING 130
7.5.1 INCREASING INCIDENCE OF DIABETES TO DRIVE ADOPTION OF ESOTERIC TESTS 130
TABLE 70 ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION) 131
TABLE 71 NORTH AMERICA: ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 131
TABLE 72 EUROPE: ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 132
TABLE 73 ASIA PACIFIC: ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 132
TABLE 74 LATIN AMERICA: ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 133
7.6 GENETIC TESTING 133
7.6.1 ADVANCEMENTS IN GENOMICS AND PROTEOMICS TO SUPPORT MARKET GROWTH 133
TABLE 75 ESOTERIC GENETIC TESTING MARKET, BY REGION, 2022-2029 (USD MILLION) 134
TABLE 76 NORTH AMERICA: ESOTERIC GENETIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 134
TABLE 77 EUROPE: ESOTERIC GENETIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 135
TABLE 78 ASIA PACIFIC: ESOTERIC GENETIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 135
TABLE 79 LATIN AMERICA: ESOTERIC GENETIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 136
7.7 NEUROLOGY TESTING 136
7.7.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET 136
TABLE 80 EXAMPLES OF ESOTERIC TESTS FOR NEUROLOGICAL DISORDERS 137
TABLE 81 ESOTERIC NEUROLOGY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION) 138
TABLE 82 NORTH AMERICA: ESOTERIC NEUROLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 138
TABLE 83 EUROPE: ESOTERIC NEUROLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 139
TABLE 84 ASIA PACIFIC: ESOTERIC NEUROLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 139
TABLE 85 LATIN AMERICA: ESOTERIC NEUROLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 140
7.8 TOXICOLOGY AND DRUG MONITORING TESTING 140
7.8.1 INCREASING CASES OF DRUG ABUSE AND ILLICIT DRUG CONSUMPTION TO DRIVE DEMAND FOR ESOTERIC TESTING 140
TABLE 86 ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET, BY REGION, 2022-2029 (USD MILLION) 141
TABLE 87 NORTH AMERICA: ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 142
TABLE 88 EUROPE: ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 142
TABLE 89 ASIA PACIFIC: ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 143
TABLE 90 LATIN AMERICA: ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 143
7.9 OTHER TYPES OF TESTING 143
TABLE 91 ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY REGION, 2022-2029 (USD MILLION) 144
TABLE 92 NORTH AMERICA: ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY COUNTRY, 2022-2029 (USD MILLION) 145
TABLE 93 EUROPE: ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY COUNTRY, 2022-2029 (USD MILLION) 145
TABLE 94 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY COUNTRY, 2022-2029 (USD MILLION) 146
TABLE 95 LATIN AMERICA: ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY COUNTRY, 2022-2029 (USD MILLION) 146
8 ESOTERIC TESTING MARKET, BY SPECIMEN 147
8.1 INTRODUCTION 148
TABLE 96 ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 148
8.2 BLOOD, SERUM, AND PLASMA 149
8.2.1 GREATER PREFERENCE AMONG HEALTHCARE PROVIDERS TO PROPEL MARKET 149
TABLE 97 ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY REGION, 2022-2029 (USD MILLION) 150
TABLE 98 NORTH AMERICA: ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 150
TABLE 99 EUROPE: ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 151
TABLE 100 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 151
TABLE 101 LATIN AMERICA: ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 152
8.3 URINE 152
8.3.1 INCREASING UTILIZATION IN ILLICIT DRUG TESTING TO BOOST DEMAND 152
TABLE 102 ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY REGION, 2022-2029 (USD MILLION) 153
TABLE 103 NORTH AMERICA: ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 153
TABLE 104 EUROPE: ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 154
TABLE 105 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 154
TABLE 106 LATIN AMERICA: ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 155
8.4 OTHER SPECIMENS 155
TABLE 107 ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY REGION, 2022-2029 (USD MILLION) 156
TABLE 108 NORTH AMERICA: ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 156
TABLE 109 EUROPE: ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 157
TABLE 110 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 157
TABLE 111 LATIN AMERICA: ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 158
?
9 ESOTERIC TESTING MARKET, BY END USER 159
9.1 INTRODUCTION 160
TABLE 112 ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 160
9.2 INDEPENDENT AND REFERENCE LABORATORIES 160
9.2.1 LARGEST AND FASTEST-GROWING END USERS OF ESOTERIC TESTS 160
TABLE 113 ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY REGION, 2022-2029 (USD MILLION) 161
TABLE 114 NORTH AMERICA: ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 161
TABLE 115 EUROPE: ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 162
TABLE 116 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 162
TABLE 117 LATIN AMERICA: ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 163
9.3 HOSPITAL-BASED LABORATORIES 163
9.3.1 INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS PERFORMED TO SUPPORT MARKET GROWTH 163
TABLE 118 ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY REGION, 2022-2029 (USD MILLION) 164
TABLE 119 NORTH AMERICA: ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 164
TABLE 120 EUROPE: ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 165
TABLE 121 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 165
TABLE 122 LATIN AMERICA: ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 166
10 ESOTERIC TESTING MARKET, BY REGION 167
10.1 INTRODUCTION 168
TABLE 123 ESOTERIC TESTING MARKET, BY REGION, 2022-2029 (USD MILLION) 168
10.2 NORTH AMERICA 169
FIGURE 31 NORTH AMERICA: ESOTERIC TESTING MARKET SNAPSHOT 170
TABLE 124 NORTH AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 171
TABLE 125 NORTH AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 171
TABLE 126 NORTH AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 172
TABLE 127 NORTH AMERICA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 172
TABLE 128 NORTH AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 173
10.2.1 NORTH AMERICA: RECESSION IMPACT 173
?
10.2.2 US 173
10.2.2.1 Favorable policies for molecular diagnostic providers to support market growth 173
TABLE 129 US: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 174
TABLE 130 US: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 175
TABLE 131 US: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 175
TABLE 132 US: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 176
TABLE 133 US: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 176
10.2.3 CANADA 176
10.2.3.1 Lack of proper reimbursements for diagnostic tests to hamper market growth 176
TABLE 134 CANADA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 178
TABLE 135 CANADA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 178
TABLE 136 CANADA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 179
TABLE 137 CANADA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 179
10.3 EUROPE 179
TABLE 138 EUROPE: ESOTERIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 180
TABLE 139 EUROPE: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 181
TABLE 140 EUROPE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 181
TABLE 141 EUROPE: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 182
TABLE 142 EUROPE: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 182
10.3.1 EUROPE: RECESSION IMPACT 182
10.3.2 GERMANY 183
10.3.2.1 Favorable government policies to propel market 183
TABLE 143 GERMANY: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 183
TABLE 144 GERMANY: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 184
TABLE 145 GERMANY: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 184
TABLE 146 GERMANY: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 185
TABLE 147 GERMANY: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 185
10.3.3 FRANCE 185
10.3.3.1 Rising demand for early disease diagnosis to drive market 185
TABLE 148 FRANCE: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 186
TABLE 149 FRANCE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 186
TABLE 150 FRANCE: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 187
TABLE 151 FRANCE: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 187
10.3.4 ITALY 187
10.3.4.1 Rapidly growing geriatric population to favor market growth 187
TABLE 152 ITALY: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 188
TABLE 153 ITALY: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 189
TABLE 154 ITALY: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 189
TABLE 155 ITALY: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 190
10.3.5 UK 190
10.3.5.1 Favorable investment scenario to drive market 190
TABLE 156 UK: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 191
TABLE 157 UK: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 191
TABLE 158 UK: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 192
TABLE 159 UK: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 192
10.3.6 SPAIN 192
10.3.6.1 High burden of chronic and infectious diseases to drive adoption of esoteric tests 192
TABLE 160 SPAIN: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 193
TABLE 161 SPAIN: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 194
TABLE 162 SPAIN: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 194
TABLE 163 SPAIN: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 195
10.3.7 REST OF EUROPE 195
TABLE 164 REST OF EUROPE: CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2045 196
TABLE 165 REST OF EUROPE: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 196
TABLE 166 REST OF EUROPE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 197
TABLE 167 REST OF EUROPE: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 197
TABLE 168 REST OF EUROPE: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 198
10.4 ASIA PACIFIC 198
FIGURE 32 ASIA PACIFIC: ESOTERIC TESTING MARKET SNAPSHOT 199
TABLE 169 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 200
TABLE 170 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 200
TABLE 171 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 201
TABLE 172 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 201
TABLE 173 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 202
10.4.1 ASIA PACIFIC: RECESSION IMPACT 202
10.4.2 JAPAN 202
10.4.2.1 Presence of well-developed healthcare system to favor market growth 202
TABLE 174 JAPAN: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 203
TABLE 175 JAPAN: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 203
TABLE 176 JAPAN: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 204
TABLE 177 JAPAN: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 204
TABLE 178 JAPAN: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 205
10.4.3 CHINA 205
10.4.3.1 China to register highest growth rate in Asia Pacific esoteric testing market during forecast period 205
TABLE 179 CHINA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 206
TABLE 180 CHINA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 206
TABLE 181 CHINA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 207
TABLE 182 CHINA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 207
TABLE 183 CHINA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 208
10.4.4 INDIA 208
10.4.4.1 Improving healthcare system to support market growth 208
TABLE 184 INDIA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 208
TABLE 185 INDIA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 209
TABLE 186 INDIA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 210
TABLE 187 INDIA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 210
TABLE 188 INDIA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 211
10.4.5 AUSTRALIA 211
10.4.5.1 Increasing incidence of chronic diseases and increasing focus on preventive healthcare to propel market 211
TABLE 189 AUSTRALIA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 212
TABLE 190 AUSTRALIA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 212
TABLE 191 AUSTRALIA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 213
TABLE 192 AUSTRALIA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 213
10.4.6 REST OF ASIA PACIFIC 213
TABLE 193 REST OF ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 214
TABLE 194 REST OF ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 215
TABLE 195 REST OF ASIA PACIFIC: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 215
TABLE 196 REST OF ASIA PACIFIC: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 216
10.5 LATIN AMERICA 216
TABLE 197 LATIN AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 217
TABLE 198 LATIN AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 217
TABLE 199 LATIN AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 218
TABLE 200 LATIN AMERICA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 218
TABLE 201 LATIN AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 219
10.5.1 LATIN AMERICA: RECESSION IMPACT 219
10.5.2 BRAZIL 219
10.5.2.1 Presence of large and well-developed pharmaceutical industry to drive market 219
TABLE 202 BRAZIL: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 220
TABLE 203 BRAZIL: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 221
TABLE 204 BRAZIL: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 221
TABLE 205 BRAZIL: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 222
10.5.3 MEXICO 222
10.5.3.1 Growth in private healthcare sector to propel market 222
TABLE 206 MEXICO: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 223
TABLE 207 MEXICO: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 223
TABLE 208 MEXICO: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 224
TABLE 209 MEXICO: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 224
10.5.4 REST OF LATIN AMERICA 224
TABLE 210 REST OF LATIN AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 225
TABLE 211 REST OF LATIN AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 226
TABLE 212 REST OF LATIN AMERICA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 226
TABLE 213 REST OF LATIN AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 227
10.6 MIDDLE EAST & AFRICA 227
10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET 227
TABLE 214 AFRICA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 228
TABLE 215 MIDDLE EAST & AFRICA: ESOTERIC TESTING MARKET, BY TEST, 2022-2029 (USD MILLION) 228
TABLE 216 MIDDLE EAST & AFRICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 229
TABLE 217 MIDDLE EAST & AFRICA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 229
TABLE 218 MIDDLE EAST & AFRICA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 230
10.7 MIDDLE EAST & AFRICA: RECESSION IMPACT 230
10.8 GCC COUNTRIES 230
10.8.1 HEALTHCARE INFRASTRUCTURE DEVELOPMENT TO DRIVE MARKET 230
TABLE 219 GCC COUNTRIES: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION) 231
TABLE 220 GCC COUNTRIES: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 232
TABLE 221 GCC COUNTRIES: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 232
TABLE 222 GCC COUNTRIES: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 233
10.8.2 GCC COUNTRIES: RECESSION IMPACT 233
11 COMPETITIVE LANDSCAPE 234
11.1 OVERVIEW 234
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 234
TABLE 223 OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS 234
11.3 REVENUE SHARE ANALYSIS 236
FIGURE 33 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN ESOTERIC TESTING MARKET, 2021-2023 (USD MILLION) 236
11.4 MARKET SHARE ANALYSIS 237
TABLE 224 ESOTERIC TESTING MARKET: DEGREE OF COMPETITION 237
FIGURE 34 ESOTERIC TESTING MARKET SHARE ANALYSIS, 2023 238
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 239
11.5.1 STARS 239
11.5.2 EMERGING LEADERS 239
11.5.3 PERVASIVE PLAYERS 239
11.5.4 PARTICIPANTS 240
FIGURE 35 ESOTERIC TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 240
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 241
TABLE 225 COMPANY FOOTPRINT 241
TABLE 226 TYPE FOOTPRINT 242
TABLE 227 TECHNOLOGY FOOTPRINT 243
TABLE 228 END-USER FOOTPRINT 243
TABLE 229 REGIONAL FOOTPRINT 244
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 245
11.6.1 PROGRESSIVE COMPANIES 245
11.6.2 STARTING BLOCKS 245
11.6.3 RESPONSIVE COMPANIES 245
11.6.4 DYNAMIC COMPANIES 245
FIGURE 36 ESOTERIC TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 246
11.6.5 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 247
TABLE 230 ESOTERIC TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 247
11.7 COMPETITIVE SCENARIO 247
11.7.1 SERVICE LAUNCHES 247
TABLE 231 ESOTERIC TESTING MARKET: SERVICE LAUNCHES, JANUARY 2021-APRIL 2024 247
11.7.2 DEALS 248
TABLE 232 ESOTERIC TESTING MARKET: DEALS, JANUARY 2021-APRIL 2024 248
11.7.3 EXPANSIONS 249
TABLE 233 ESOTERIC TESTING MARKET: EXPANSIONS, JANUARY 2021-APRIL 2024 249
11.8 VALUATION AND FINANCIAL METRICS OF ESOTERIC TESTING VENDORS 250
FIGURE 37 EV/EBITDA OF TOP 3 COMPANIES IN ESOTERIC TESTING MARKET 250
FIGURE 38 EV/REVENUE OF TOP 3 COMPANIES IN ESOTERIC TESTING MARKET 250
FIGURE 39 1-YEAR PRICE TOTAL RETURN OF TOP 3 COMPANIES IN ESOTERIC TESTING MARKET 251
FIGURE 40 5-YEAR BETA OF TOP 3 COMPANIES IN ESOTERIC TESTING MARKET 251
12 COMPANY PROFILES 252
(Business overview, Products offered, Recent Developments, MNM view)*
12.1 MAJOR PLAYERS 252
12.1.1 LABCORP 252
TABLE 234 LABCORP: BUSINESS OVERVIEW 252
FIGURE 41 LABCORP: COMPANY SNAPSHOT (2023) 252
TABLE 235 LABCORP: SERVICES OFFERED 253
TABLE 236 LABCORP: SERVICE LAUNCHES, JANUARY 2021-APRIL 2024 254
TABLE 237 LABCORP: DEALS, JANUARY 2021-APRIL 2024 255
TABLE 238 LABCORP: EXPANSIONS, JANUARY 2021-APRIL 2024 256
?
12.1.2 QUEST DIAGNOSTICS 258
TABLE 239 QUEST DIAGNOSTICS: BUSINESS OVERVIEW 258
FIGURE 42 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2023) 259
TABLE 240 QUEST DIAGNOSTICS: SERVICES OFFERED 259
TABLE 241 QUEST DIAGNOSTICS: SERVICE LAUNCHES, JANUARY 2021-APRIL 2024 262
TABLE 242 QUEST DIAGNOSTICS: DEALS, JANUARY 2021-APRIL 2024 262
TABLE 243 QUEST DIAGNOSTICS: EXPANSIONS, JANUARY 2021-APRIL 2024 264
12.1.3 OPKO HEALTH, INC. 265
TABLE 244 OPKO HEALTH, INC.: BUSINESS OVERVIEW 265
FIGURE 43 OPKO HEALTH, INC.: COMPANY SNAPSHOT (2023) 266
TABLE 245 OPKO HEALTH, INC.: SERVICES OFFERED 266
TABLE 246 OPKO HEALTH, INC.: DEALS, JANUARY 2021-APRIL 2024 267
12.1.4 H.U. GROUP HOLDINGS, INC. 269
TABLE 247 H.U. GROUP HOLDINGS, INC.: BUSINESS OVERVIEW 269
FIGURE 44 H.U. GROUP HOLDINGS, INC.: COMPANY SNAPSHOT (2023) 269
TABLE 248 H.U. GROUP HOLDINGS, INC.: SERVICES OFFERED 270
TABLE 249 H.U. GROUP HOLDINGS, INC.: DEALS, JANUARY 2021-APRIL 2024 270
12.1.5 SONIC HEALTHCARE LIMITED 271
TABLE 250 SONIC HEALTHCARE LIMITED: BUSINESS OVERVIEW 271
FIGURE 45 SONIC HEALTHCARE LIMITED: COMPANY SNAPSHOT (2023) 272
TABLE 251 SONIC HEALTHCARE LIMITED: SERVICES OFFERED 272
TABLE 252 SONIC HEALTHCARE LIMITED: DEALS 273
12.1.6 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MFMER) 274
TABLE 253 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: BUSINESS OVERVIEW 274
TABLE 254 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: SERVICES OFFERED 274
12.1.7 EUROFINS SCIENTIFIC 275
TABLE 255 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 275
FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023) 276
TABLE 256 EUROFINS SCIENTIFIC: SERVICES OFFERED 276
TABLE 257 EUROFINS SCIENTIFIC: SERVICE LAUNCHES, JANUARY 2021-APRIL 2024 277
TABLE 258 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021-APRIL 2024 277
12.1.8 STANFORD HEALTH CARE 278
TABLE 259 STANFORD HEALTH CARE: BUSINESS OVERVIEW 278
TABLE 260 STANFORD HEALTH CARE: SERVICES OFFERED 278
TABLE 261 STANFORD HEALTH CARE: SERVICE LAUNCHES, JANUARY 2021-APRIL 2024 278
TABLE 262 STANFORD HEALTH CARE: DEALS, JANUARY 2021-APRIL 2024 279
12.1.9 FOUNDATION MEDICINE, INC. 280
TABLE 263 FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW 280
TABLE 264 FOUNDATION MEDICINE, INC.: SERVICES OFFERED 280
TABLE 265 FOUNDATION MEDICINE, INC.: DEALS, JANUARY 2021-APRIL 2024 281
?
12.1.10 KINDSTAR GLOBALGENE TECHNOLOGY, INC. 282
TABLE 266 KINDSTAR GLOBALGENE TECHNOLOGY, INC.: BUSINESS OVERVIEW 282
FIGURE 47 KINDSTAR GLOBALGENE TECHNOLOGY, INC.: COMPANY SNAPSHOT (2023) 282
TABLE 267 KINDSTAR GLOBALGENE TECHNOLOGY, INC.: SERVICES OFFERED 283
12.1.11 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC 284
TABLE 268 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC: BUSINESS OVERVIEW 284
TABLE 269 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC: SERVICES OFFERED 284
12.1.12 THYROCARE TECHNOLOGIES LIMITED 285
TABLE 270 THYROCARE TECHNOLOGIES LIMITED: BUSINESS OVERVIEW 285
FIGURE 48 THYROCARE TECHNOLOGIES LIMITED: COMPANY SNAPSHOT (2023) 285
TABLE 271 THYROCARE TECHNOLOGIES LIMITED: SERVICES OFFERED 286
12.1.13 ACM GLOBAL LABORATORIES 287
TABLE 272 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW 287
TABLE 273 ACM GLOBAL LABORATORIES: SERVICES OFFERED 287
12.2 OTHER PLAYERS 288
12.2.1 NMS LABS 288
12.2.2 HEALTHQUEST ESOTERICS 288
12.2.3 CERBA XPERT 289
12.2.4 LEOLABS, INC. 290
12.2.5 FLOW HEALTH 290
12.2.6 INVITAE CORPORATION 291
12.2.7 MYRIAD GENETICS, INC. 292
12.2.8 ARUP LABORATORIES 293
12.2.9 FULGENT GENETICS 294
12.2.10 BIOMONTR LABS 295
12.2.11 LABGENOMICS 295
*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX 296
13.1 DISCUSSION GUIDE 296
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 300
13.3 CUSTOMIZATION OPTIONS 302
13.4 RELATED REPORTS 303
13.5 AUTHOR DETAILS 304
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security